NUTX · Nutex Health Inc.

The thesis

Nutex Health's shares have recovered on a reset of arbitration costs. Revenue still has to confirm that reset. The third-quarter report, which Yahoo Finance lists for about 5 November 2026, settles it. It needs to show recurring contract services costs down by the 25-30% the company guided and revenue at or above the $210.8 million reported for Q2 2026.

The shares closed at $211.66 on 30 September 2026, 3.8% below the 52-week high of $220.11. The 14-day relative strength index (RSI) stood at 59.6, which is firm but not stretched. Since the 19 September 2026 note, the new information has been about the shares rather than the business: two price-target increases and a second exchange listing. No new operating data has been published.

The narrative is maturing: the cost reset has been public since the 6 August 2026 results, and the news since then has come from analysts raising targets and a Nasdaq Texas listing that began trading on 23 September 2026. That keeps attention on the name without testing the case. The case weakens on a weekly close below $180, under the $193.24 reference close of 4 September 2026 that StockAnalysis cited, or on a Q3 report that shows the Q2 savings were mostly a one-time catch-up.

Bullish and bearish views on Nutex Health Inc.

The bull case on Nutex Health Inc. (NUTX), in brief: Guidance points to lasting cost savings. The bear case: Revenue also came in below the $215.0 million consensus that Benzinga reported.

Bull case

• Guidance points to lasting cost savings. In its 6 August 2026 release, Nutex said the amended HaloMD agreement moved certain fees to a pay-on-collected basis. It expects an "approximate 25-30% reduction in normalized historical contract services expenses prospectively." The amendment, disclosed in a 21 July 2026 filing, applies the revised service fees to settlements obtained from 1 July 2026, so Q3 is the first full quarter under the new terms.
• Cash generation backs reported earnings. Operating cash flow was $109.7 million for the six months ended 30 June 2026, against $78.2 million a year earlier.
• Buybacks are shrinking the share count. The company repurchased and retired $50.7 million of common stock in the six months ended 30 June 2026, according to the same release.
• Analyst targets keep rising. B. Riley raised its target to $325 from $290 on 4 September 2026. Freedom Capital Markets raised its target to $306 from $280 on 25 September 2026. Both firms kept Buy ratings.
• Patient volume is still growing. Hospital Division visits were 49,962 in Q2 2026, up 9.6% year over year and up 6.3% at hospitals open in both periods, per the 6 August 2026 release.

Bear case

• Revenue also came in below the $215.0 million consensus that Benzinga reported.
• Q2 costs include a one-time catch-up. Contract services expense fell to $1.1 million from $61.1 million. The company attributed the $52.3 million reduction to a "retroactive amendment" with HaloMD. The Q2 figure does not show what the recurring cost will be.
• Revenue depends on arbitration awards. The company says it prevails in over 85% of independent dispute resolution (IDR) cases under the No Surprises Act and collects on average over 80% of award amounts (6 August 2026 release). A change to federal rules or to insurer payment behaviour would hit revenue directly.
• Legal overhang is unresolved. An SEC inquiry into the disclosure of HaloMD exposure and the collectibility of arbitration revenue remains open, alongside a securities class action and a derivative suit. A separate class action over the August 2026 data theft was filed in federal court in Houston on 27 August 2026.

Price setup

The close of $211.66 on 30 September 2026 sits 3.8% below the 52-week high of $220.11. The shares are up 7.7% over three months. They have recovered from the $162.98 close of 17 July 2026, recorded before the Q2 report. Since the 6 August 2026 results, the shares have moved up on analyst target increases rather than new company data.

Two price levels frame the shares. A weekly close above $220.11 would mark a new 52-week high. A weekly close below $180 would give back the post-results advance through the $193.24 close of 4 September 2026. The shares have a history of double-digit single-day moves on one headline, so a wide range around the November report is consistent with past trading.

Crowding is moderate. The RSI of 59.6 does not signal an overheated advance. Five analysts cover the stock, according to StockAnalysis, and the two September target increases both came from existing coverage. The Q3 report falls within the next three months.

Catalysts, next 30 days

• ~23 October 2026 (est.): Nasdaq publishes short interest for the mid-October settlement date. Two readings in a row show which way short selling is moving.
• Mid-to-late October 2026 (est.): Nutex announces its Q3 results date. In April the company announced its Q1 date eight days before the release.
• ~5 November 2026 (est., outside the 30-day window): Q3 FY2026 results. This is the event the case turns on: the first full quarter of contract services costs under the amended HaloMD terms, and whether revenue holds at the Q2 level of $210.8 million.

Elapsed catalysts

• ~9 October 2026 (est.): Nasdaq publishes short interest for the 30 September 2026 settlement date. It shows whether short sellers covered or rebuilt their bets as the shares approached the high. (passed 4d ago)

What would change the view

The case breaks if Q3 contract services costs, excluding any retroactive credit, do not show the 25-30% reduction from historical levels the company guided on 6 August 2026. It also breaks if Q3 revenue falls below the Q2 figure of $210.8 million, which would be a third straight sequential decline. A collection rate on IDR awards below the 80% the company cited, or another write-down of ineligible arbitration claims, would undermine the revenue base.

On price, a weekly close below $180 would mean the market has given back the post-results advance. An SEC enforcement action over arbitration-revenue disclosure would end the case regardless of price.

The case would strengthen if Q3 showed recurring contract services costs at the guided level, revenue at or above $210.8 million, and a weekly close above the $220.11 52-week high.

What it trades with

The shares trade mostly on company-specific news: arbitration economics, the HaloMD contract, litigation and analyst actions. They have tracked hospital and managed-care stocks only loosely. The main outside factor is federal policy on the No Surprises Act IDR process. A Centers for Medicare & Medicaid Services (CMS) rule or fee change, such as the cut in the IDR administrative fee to $15 per party effective 11 June 2026, reprices the business directly. Few analysts cover the stock, so a single rating change can move it sharply, independent of the broader market.